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From November 2007 to April 2011 we performed 170 minimally invasive
mitral valve repairs. Among them one of us did perform this modified “respect
but not resect” strategy for 70 patients. No resection was needed except for
one endocarditis. Perioperative mortality was 0% . None SAM occur during
or after procedure. During perioperative period no regurgitation or grade 1
regurgitation were found in 44 patients. Only one had a grade 2 regurgitation
at discharge. During follow-up none redo surgery was needed for repair dys-
function , one patient scheduled for endocarditis.
This is a simple and easy procedure to perform, repair of mitral regurgita-
tion is efficient. It is an easy way to evaluate mitral coaptation and avoid SAM
without needing external evaluation before weaning bypass. Posterior leaflet
is always “smiling” as in Dr Carpentier recommandations. Procedure is safe
with good short-terms results. Long-term evaluation is still needed.
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Context: Observational studies showed that the rate of valve surgery in
infective endocarditis (IE) increased over time and that it may be associated
with lower in-hospital mortality.
Objective: To update the description of surgery in IE in France.
Design: Prospective population-based observational study conducted in 2008.
Setting: All medical facilities from 6 French regions representing 32% of
the whole French population aged 18 years and older.
Patients: 497 adults with definite IE admitted to hospital in 2008.
Results: 201 patients (40%) were operated on during the active phase of IE:
182 had left-heart (± right-heart) surgery, 10 had right-heart only surgery and 9
had surgical lead extraction without valve surgery. Among 398 patients with left-
sided (± right-sided) IE, 50% had no previously known heart disease, 23% had at
least one prosthetic valve. Heart failure was present in 35% and ischemic stroke
in 28%. IE was mitral in 45%, aortic in 40% and aortic + mitral in 15%. Echocar-
diography was positive for IE in 98%. Microorganisms were streptococcaceae in
55% and staphylococcaceae in 30%. Time elapsed between hospital admission
and indication for surgery was 10±13 days, it was 15±13 days between hospital
admission and surgery. Indication for surgery was hemodynamic in 71% of the
patients, infectious in 40% and prevention of embolism in 54%. Women were
operated less often than men (36% vs 49%; p<0.03). As compared to non-operated
patients, operated patients were younger (58 vs 67 years; p<0.0001), had more
often heart failure (44% vs 28%; p=0.0006), vegetation larger than 10 mm (82%
vs 58%; p<0.0001), abscess (39% vs 13%; p<0.0001) and less often mitral IE
(33% vs 55%; p<0.0001); distribution of microorganisms was not statistically dif-
ferent; in-hospital mortality was lower (20% vs 26%) but that was not statistically
significant.
Conclusion: Surgery is frequently indicated in IE. There is a trend toward
lower in-hospital mortality in operated patients.
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Aims: Transcatheter aortic valve implantation (TAVI) is an emerging tech-
nique for the treatment of severe aortic stenosis (AS) in high-surgical-risk
patients. It is unclear whether it compares favourably with surgical aortic
valve replacement (SAVR) in a high-risk non selected population.
Methods and Results: This observational prospective cohort study
included all consecutive high-risk patients with severe AS treated by SAVR
or by TAVI. Trans femoral (TF-TAVI) approach was the first access option.
Trans apical (TA) approach was used if TF access contra-indicated. Co-pri-
mary end points were 1 year and 30-day all-cause mortality. Results were
described using Valve Academic Research Consortium (VARC) definitions.
143 patients were included: 58 underwent SAVR, 60 TF-TAVI and 25 TA-
TAVI. Mean baseline characteristics were the same in the 3 groups except for
risk scores and NYHA status, worse for TF- and TA-TAVI patients than for
SAVR patients. All-cause mortality in SAVR, TF-TAVI and TA-TAVI groups
were respectively 25.9%, 18.3% and 36% at 1 year (p=0.22); and 17%, 5 and
16% at 30 days (TF-TAVI vs SAVR: p=0.034, TA-TAVI vs SAVR: p=0.999).
At 30 days myocardial infarction and major stroke only occurred in SAVR
group (7% and 2% respectively). Life-threatening and/or major bleedings
were 75% in SAVR group, 53% and 80% in TF and TA-TAVI groups
(p=0.016 TF-TAVI vs SAVR, p=0.624 TA-TAVI vs SAVR). Major vascular
complications were 8% in the TF-TAVI, 12% in the TA-TAVI (p=0.860).
6 patients (10%) of the SAVR group needed reintervention for haemostasis or
pericardial draining. 1 year and 30-day NYHA functional status and aortic
prostheses mean gradient were the same in all groups.
Conclusion: This observational study provide a snapshot of the 1 year and
30-day outcome after modern conventional SAVR and TF- or TA-TAVI, in an
“real-life” high-risk AS population. It is also probably one of the first studies
to describe this outcome using VARC endpoints definitions.
192
Invasive assessment of atrioventricular conduction changes following
transcatheter aortic valve implantation with self-expandable or bal-
loon-expandable prosthesis
A Rollin [Orateur] (1), N Dumonteil (1), P Mondoly (1), B Marcheix (1),
A Duparc (1), N Boudou (1), Thibault Lhermusier (1), M Gautier (1),
D Tchetche (2), M Delay (1), Ph Maury (1), Didier Carrié (1)
(1) CHU Rangueil, Maladies Cardiovasculaires et Métaboliques, Tou-
louse, France  (2) Clinique Pasteur, Toulouse, France
Background: Atrio-ventricular block (AVB) is one of the complications
after transcatheter aortic valve implantation (TAVI), and is more frequent after
implantation of a Medtronic CoreValve (MCV) than after implantation of an
Edwards Sapien prosthesis (ES).
The aim of this prospective study was to quantify and compare by invasive
measurement the exact influence of TAVI with MCV or ES valve on atrioven-
tricular conduction.
Methods: between February 2010 and March 2011, consecutive patients who
underwent TAVI with a MCV or an ES valve were included in this prospective,
single center study. The His-Ventricle (HV) interval was measured during an elec-
trophysiology study (EPS) before and at least 4 days after the procedure. Patients
with pre-existent permanent PM implanted for AVB were excluded
Results: 60 patients were included. 25 (42%) were treated with a MCV,
and 35 (58%) with an ES valve. Mean age was 83+/–6 years, 62% men with
no significant difference of baseline clinical, ECG, echocardiographic data,
Logistic EuroScore and STS Score between MCV and ES groups. There was
no peri-procedural death. HV interval measurement was feasible in all
patients. 19 patients (32%) needed implantation of a permanent PM. Indica-
tion was persistent complete AVB in 12 patients (20%) and transient high
grade AVB in 4 patients (7%). PM implantation was required in 6 patients
(17%) with ES valve and 13 patients (52%) with MCV (Odds Ratio: 6.8, (95%
CI 1.9-24.8) p<0.01). HV interval remained stable (increased duration 5 ms)
in 10 patients (30%) with ES valve and in 5 patients (20%) with MCV (p: 0.
15). HV interval was prolonged by 10ms or more after procedure in
12 patients (35%) with ES valve and in 17 patients (68%) with MCV (Odds
Ratio: 5. (95% CI 1. 5-16.9) p<0.01).
Conclusion: This study supports the fact that atrioventricular and particu-
larly infrahisian conductive tissue is frequently impaired after TAVI. This
damage is more frequent and more severe with MCV compared with ES valve.
